Data_Sheet_1_Intensified Antituberculosis Therapy Regimen Containing Higher Dose Rifampin for Tuberculous Meningitis: A Systematic Review and Meta-Analysis.PDF

BackgroundTuberculous meningitis is difficult to diagnose and is associated with high mortality. Recently, several studies evaluated the intensified regimen containing higher dose rifampin to treat tuberculous meningitis. However, this topic remains to be concluded. Therefore, this systematic review and meta-analysis was conducted to evaluate pharmacokinetics parameters, safety, and survival benefits of high-dose rifampin for tuberculous meningitis.MethodData were searched from PubMed, EMBASE, The Cochrane Library, and Web of Science for studies describing an antituberculosis regimen including a higher dose of rifampin for patients with tuberculous meningitis. The quality of eligible studies was evaluated via The Cochrane Risk of Bias Tool. The meta-analysis was performed by Review Manager 5.3 software, the synthesis of the data was shown in mean difference (MD) or relative risk (RR), and 95% confidence intervals (CIs).ResultsThere were six randomized control trails included in this meta-analysis. The results showed that the concentration in plasma and cerebrospinal fluid (CSF) were significantly higher in the intervention group than the standard group [MD = 22.08, 95%CI (16.24, 27.92), p 0−24) of rifampin [MD 203.56, 95%CI (153.07, 254.05), p ConclusionThis meta-analysis suggested that the intensified treatment regimen including a higher dose of rifampin significantly increased the rifampin concentration both in the plasma and CSF, and it was safe in patients with tuberculous meningitis, but resulted in no improvement in survival rates.</p

Demographic data of participants, their lung function and methacholine challenge test results (n = 46).

<p>Demographic data of participants, their lung function and methacholine challenge test results (n = 46).</p

Health-related quality of life scores.*

<p>Note: *The values are given as the mean±the standard deviation.</p

Pearson correlation coefficients between SF-36 scores and clinical and spirometric parameters [r (P value)].

<p>Pearson correlation coefficients between SF-36 scores and clinical and spirometric parameters [r (P value)].</p

Association of inhaled corticosteroid usage with clinical parameters, airway responsiveness indices and HRQL scores.

<p>Note: *The values are given as the mean ± the standard deviation.</p

Comparison of SF-36 health-related quality of life scores according to the response to methacholine challenge test.

<p>Comparison of SF-36 health-related quality of life scores according to the response to methacholine challenge test.</p

Pearson correlation coefficients between the airway responsiveness indices and clinical and spirometric parameters [r (P value)].

<p>Pearson correlation coefficients between the airway responsiveness indices and clinical and spirometric parameters [r (P value)].</p

Additional file 1 of Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis

Additional file 1: Table S1. Search strategy. Table S2. The Jadad scale of randomized controlled trials. Table S3. The Newcastle-Ottawa quality assessment scale of cohort studies

Additional file 2 of Association between a single nucleotide polymorphism of the IL23R gene and tuberculosis in a Chinese Han population: a case‒control study

Supplementary Material

Additional file 3 of Association between a single nucleotide polymorphism of the IL23R gene and tuberculosis in a Chinese Han population: a case‒control study

Supplementary Material